Teleflex (TFX), HealthTrust Rebond on Respiratory Products

The respiratory division of Teleflex IncorporatedTFX has recently entered into a new group purchasing agreement with HealthTrust Purchasing Group ("HPG") for respiratory heaters and accessories. The agreement by the name The Respiratory Heaters & Accessories (HPG-6071) became effective on Dec 1, 2017.

The agreement covers Teleflex's full line of Active Humidification, Non Invasive Ventilation (NIV) and High Flow Nasal Cannula Therapy ("HFNCT") products. More than 400 member hospitals of HealthTrust can now access Teleflex's wide range of humidification products including the Hudson RCI Neptune Heated Humidifier with ConchaSmart Technology and ISO-Gard Heated Wire Circuit Technology besides the recent introduction of Comfort Flo Plus High Flow Nasal Cannula.

The contract also complements Teleflex's existing General Respiratory Agreement (HPG-184) with HealthTrust. Both these contracts - exclusive for Teleflex - provide HPG members with an opportunity to consolidate their respiratory purchases with a single supplier.

Notably, HFNCT has been growing at 20% rate year over year. This therapy has been shown to improve patient outcomes and reduce 90-day mortality rates compared with noninvasive ventilation and Standard Oxygen Therapy. Based on this data, we expect Teleflex's deal with HealthTrust to be strategically accretive to the former and might as well boost its top line significantly in the coming period.

Taking cues from above, Teleflex has been putting in a lot of efforts on strategic expansion and top-line growth. In September, the company had made a substantial investment in the growing field of Urology. It has made a $1.1 billion acquisition of NeoTract, a privately-held developer of minimally invasive and clinically effective devices.

Apart from strengthening Teleflex's presence in the Urology market, the company expects this buyout to accelerate the company's near-term sales growth trajectory and provide it with significant sales channel opportunity. Additionally, this should enhance Teleflex's organic growth profile in the long term.

Over the past three months, Teleflex has been trading above the broader industry . The stock has gained 5.2% compared with the broader industry's 1.1% gain during the period.

Zacks Rank & Key Picks

Teleflex carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are PetMed Express, Inc. (PETS), Align Technology, Inc. (ALGN) and Luminex Corporation (LMNX). Notably, PetMed, Align Technology and Luminexsport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 97.5% over a year.

Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 133% in a year.

Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 5.2% over the past three months.

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PetMed Express, Inc. (PETS): Free Stock Analysis Report

Teleflex Incorporated (TFX): Free Stock Analysis Report

Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report

Align Technology, Inc. (ALGN): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.